Skip to main content
. 2024 Jul 18;12(7):163. doi: 10.3390/diseases12070163

Figure 1.

Figure 1

Expression of TET2 and tumor suppressor proteins after DNMTi treatment in HCT116 DNMT1+/+ and DNMT1–/– cells. (a) TET2 upregulation and p16ink4A re-expression upon exposure to decitabine and aza-T-dCyd for 72h and 96 h in DNMT1–/– cells. irProtein, irrelevant protein. (b) TET2 upregulation and p16ink4A and p15ink4B re-expression after decitabine and azacitidine treatment for 72 h. (c) Confirmation of TET2 upregulation and p16ink4A re-expression upon exposure to aza-T-dCyd for 72 h in DNMT1–/– versus DNMT1+/+ cells. Aza-TdC, aza-T-dCyd; DAC, decitabine; AZA, azacitidine.